Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01496443 · ClinicalTrials.gov registry record · Phase 1
TAK-875 Glimepiride Drug-Interaction Study
A Phase 1 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT01496443 is a Phase 1 study that has completed, run by Takeda. The registered enrollment target is 28 participants.
The verdict
NCT01496443, a Phase 1 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the pharmacokinetics and safety of TAK-875, once daily (QD), with and without glimepiride in participants with type 2 diabetes mellitus (T2DM).
Interventions
- DRUG TAK-875 and Glimepiride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2012-01 |
| Est. Completion | 2012-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01496443
The ClinicalTrials.gov registry entry for NCT01496443 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TAK-875 and Glimepiride is the first listed.
NCT01496443 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01496443 about?
NCT01496443 is a clinical study titled "TAK-875 Glimepiride Drug-Interaction Study". The purpose of this study is to determine the pharmacokinetics and safety of TAK-875, once daily (QD), with and without glimepiride in participants with type 2 diabetes mellitus (T2DM).
What is the current status of trial NCT01496443?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2012-01. Estimated completion is 2012-05.
What interventions are being tested in trial NCT01496443?
The interventions under investigation include: TAK-875 and Glimepiride (DRUG).
Who is sponsoring clinical trial NCT01496443?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.